BioNTech cut the ribbon on a messenger-RNA production and research facility at La Trobe University in Melbourne on 20 October, a site built around clinical-scale manufacturing rather than commercial output. The German biotech is pairing that capacity with research work on the same campus, tying clinical supply and discovery under one roof.
The Australian opening lands in a crowded October for the company, which has also been reshaping who pays for what across its partnered pipeline. Most consequential is the option BioNTech exercised in its alliance with Roche and Genentech, announced yesterday. From 1 January 2027, future research and development costs for the shared program are, in principle, to sit with Roche and Genentech. BioNTech stands to collect royalties if development and commercialization succeed — a payoff that remains contingent on the program clearing those hurdles. Guidance for its own adjusted R&D spend and adjusted sales and administrative costs was left untouched.
A quarter that swung back into the black
Those partnership mechanics sit alongside third-quarter 2026 figures that tell two stories at once. Revenue came in at EUR 1,289.2 million, down from EUR 1,518.9 million a year earlier. Net income, though, flipped to a EUR 184.5 million profit from a EUR 28.7 million loss in the prior-year period.
One revenue line worth flagging: the strategic partnership with Bristol Myers Squibb around the drug candidate Pumitamig contributed EUR 613 million in the third quarter, a figure the company detailed yesterday alongside its quarterly report. Roughly two weeks earlier, the two partners had flagged encouraging phase-2 results from the ROSETTA Lung-107 trial, which tested Pumitamig combined with docetaxel in advanced non-small-cell lung cancer. Enrolled patients had seen their disease progress after a first-line regimen of immunotherapy and chemotherapy.
Should investors sell immediately? Or is it worth buying BioNTech?
Nine-month picture stays red
Zoom out and the year-to-date numbers look less rosy. Across the first nine months of 2026, BioNTech posted revenue of EUR 1,512.9 million against a net loss of EUR 1,168.2 million under IFRS. The company also nudged up the floor of its 2026 revenue guidance to EUR 1.7 billion from EUR 1.6 billion, holding the top end at EUR 1.9 billion.
On the clinical front, a second collaboration surfaced on 22 October, this time with Gilead Sciences. The deal covers the supply of study drugs to test Pumitamig in combination with Gilead’s sacituzumab govitecan. The vehicle is a global phase-3 trial, ROSETTA Breast-01, subject to regulatory clearance. It targets patients with previously untreated, locally advanced or metastatic triple-negative breast cancer whose tumors show low or no PD-L1 expression.
Not everything in October has been forward-looking. A report yesterday from dpa-AFX said BioNTech’s works council has criticized management’s treatment of employees, airing its concerns in a letter to the executive board — a note of internal friction running parallel to the company’s broader transformation.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from November 4 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 4.
BioNTech: Buy or sell? Read more here...
